Comparative evaluation of 4 commercial modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines against heterologous dual Korean PRRSV-1 and PRRSV-2 challenge.

BACKGROUND

Four commercial porcine reproductive and respiratory syndrome virus (PRRSV) modified-live vaccines (MLV) was compared to protect growing pigs against dual challenge of PRRSV-1 and PRRSV-2.

METHODS

Two of the vaccines were based on PRRSV-1, and two on PRRSV-2. A total of 72 PRRSV-naïve pigs were divided into six groups (12 pigs/group).

RESULTS

Two PRRSV-1 MLV-vaccinated and two PRRSV-2 MLV-vaccinated groups reduced significantly (p < .05) genomic copies of PRRSV-1 in their sera compared to the unvaccinated challenged group. Two PRRSV-2 MLV-vaccinated groups reduced significantly (p < .05) fewer genomic copies of PRRSV-2 in their sera whereas two PRRSV-1 MLV-vaccinated groups were unable to reduce genomic copies of PRRSV-2 compared to unvaccinated challenged groups. Two PRRSV-1 MLV-vaccinated groups induced a stronger PRRSV-1 specific IFN-γ-SC response, while two PRRSV-2 MLV-vaccinated groups induced a stronger PRRSV-2 specific IFN-γ-SC response. Two PRRSV-2 MLV-vaccinated groups showed significantly (p < .05) lower mean macroscopic and microscopic lung lesion scores compared to two PRRSV-1 MLV-vaccinated groups.

CONCLUSIONS

These data demonstrated that two PRRSV-2 vaccines were efficacious and exhibited similar protection while, two PRRSV-1 vaccines were largely ineffective against the dual challenge.